The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Dichlorobis(pyridine)platinum(II)(SMILESS: [Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2,cas:15227-42-6) is researched.Related Products of 51856-79-2. The article 《Quantitative measurement of the reduction of platinum(iv) complexes using X-ray absorption near-edge spectroscopy (XANES)》 in relation to this compound, is published in Metallomics. Let’s take a look at the latest research on this compound (cas:15227-42-6).
The platinum(ii) drugs cisplatin, carboplatin and oxaliplatin are usefully employed against a range of malignancies, but toxicities and resistance have spurred the search for improved analogs. This has included investigation of the platinum(iv) oxidation state, which provides greater kinetic inertness. It is generally accepted that Pt(iv) complexes must be reduced to Pt(ii) for activation. As such, the ability to monitor reduction of Pt(iv) complexes is critical to guiding the design of candidates, and providing mechanistic understanding. Here we report in full that the white line height of X-ray absorption near-edge spectra (XANES) of Pt complexes, normalized to the post-edge min., can be used to quant. determine the proportion of each oxidation state in a mixture A series of Pt(iv) complexes based on the Pt(ii) complexes cisplatin and transplatin were prepared with chlorido, acetato or hydroxido axial ligands, and studies into their reduction potential and cytotoxicity against A2780 human ovarian cancer cells were performed, demonstrating the relationship between reduction potential and cytotoxicity. Anal. of white line height demonstrated a clear and consistent difference between Pt(ii) (1.52 ± 0.05) and Pt(iv) (2.43 ± 0.19) complexes. Reduction of Pt(iv) complexes over time in cell growth media and A2780 cells was observed by XANES, and shown to correspond with their reduction potentials and cytotoxicities. We propose that this method is useful for monitoring reduction of metal-based drug candidates in complex biol. systems.
There is still a lot of research devoted to this compound(SMILES：[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2)Product Details of 15227-42-6, and with the development of science, more effects of this compound(15227-42-6) can be discovered.
Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem